Five years survival rate in cervical cancer patients by stages (FIGO 2018) in National cancer institute of Thailand
Keywords:
Cervical cancer, survival rate, cervical cancer in ThailandAbstract
Abstract
Objectives: This study was conducted to determine the survival rate of cervical cancer patients who received treatment at the National Cancer Institute of Thailand from the time of diagnosis until the end of treatment, and to identify the factors that affect the survival rate.
Material and Methods: Medical records of cervical cancer patients from 2017-2020 were reviewed. Only patients who started treatment and finished all treatments in National cancer institute of Thailand were included
Results: 531 patients with cervical cancers were analyzed. Mean age was 51. Most cases were squamous cell carcinoma at 75.4%, followed by adenocarcinoma at 18.9%. The distribution of disease was 24.2%, 34%, 35.4% and 6.4% in stage I, II, II, and IV. The 5-year survival rates are 88% for stage 1, 71% for stage 2, 74% for stage 3, and 40% for stage 4. And we found that only two factors significantly affected the 5 years survival rate were histology and disease stage.
Conclusion: The overall five-year survival rate of cervical cancer patients treated at the National Cancer Institute is favorable and comparable to those in developed countries and other regions in Asia.
Keywords : Cervical cancer, survival rate, cervical cancer in Thailand
References
Chhikara BS, Parang K. Global Cancer Statistics 2022: the trends projection analysis. Chem Biol Lett [Internet]. 2023 Jan. 2 [cited 2025 Mar. 27];10(1):451. Available from: https://pubs.thesciencein.org/journal/index.php/cbl/article/view/451
Cancer in Thailand [Internet]. Nci.go.th. [cited 2022 Dec 12]. Available from: https://www.nci.go.th/e_book/cit_x/index.html
NCI 2021 [Internet]. Nci.go.th. [cited 2022 Nov 18]. Available from: https://www.nci.go.th/e_book/hosbased_2564/index.html.
Singh GK, Azuine RE, Siahpush M. Global inequalities in cervical cancer incidence and mortality are linked to deprivation, low socioeconomic status, and human development. Int J MCH AIDS [Internet]. 2012;1(1):17–30. Available from: http://dx.doi.org/10.21106/ijma.12.
Cancer of the cervix uteri - cancer stat facts [Internet]. SEER. [cited 2022 Dec 12]. Available from: https://seer.cancer.gov/statfacts/html/cervix.html
Muhamad NA, Kamaluddin MA, Adon MY, Noh MA, Bakhtiar MF, Ibrahim Tamim NS, et al. Survival rates of cervical cancer patients in Malaysia. Asian Pac J Cancer Prev [Internet]. 2015;16(7):3067–72. Available from: http://dx.doi.org/10.7314/apjcp.2015.16.7.3067
Balasubramaniam G, Gaidhani RH, Khan A, Saoba S, Mahantshetty U, Maheshwari A. Survival rate of cervical cancer from a study conducted in India. Indian J Med Sci [Internet]. 2020;73(203):203–11. Available from: http://dx.doi.org/10.25259/ijms_140_2020
Bhatla N, Berek JS, Fredes C. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet [Internet]. 2019;147(2):129–35. Available from: http://dx.doi.org/10.1002/ijgo.12969.
Bangsomboon P. Survival Rate of Cervical Cancer Patients According to the 2018 FIGO Staging System: A tertiary hospital based study, Vajira Hospital, Bangkok. 2022; Available from: http://dx.doi.org/10.14456/TJOG.2022.8
Muhamad NA, Kamaluddin MA, Adon MY, Noh MA, Bakhtiar MF, Ibrahim Tamim NS, et al. Survival rates of cervical cancer patients in Malaysia. Asian Pac J Cancer Prev [Internet]. 2015;16(7):3067–72. Available from: http://dx.doi.org/10.7314/apjcp.2015.16.7.3067
Tshewang U, Satiracoo P, Lenbury Y. Survival analysis of cervical cancer patients: A case study of Bhutan. Asian Pac J Cancer Prev [Internet]. 2021;22(9):2987–93. Available from: http://dx.doi.org/10.31557/APJCP.2021.22.9.2987
Shrestha AD, Neupane D, Vedsted P, Kallestrup P. Cervical Cancer prevalence, incidence and mortality in low and middle income countries: A systematic review. Asian Pac J Cancer Prev [Internet]. 2018;19(2):319–24. Available from: http://dx.doi.org/10.22034/APJCP.2018.19.2.319
Ferreira da Silva I, Ferreira da Silva I, Koifman RJ. Cervical cancer treatment delays and associated factors in a cohort of women from a developing country. J Glob Oncol [Internet]. 2019;5(5):1–11. Available from: http://dx.doi.org/10.1200/JGO.18.00199
National cancer institute. Service plan 2566-2570 [internet]. 2023 [cited 2024 October 1].Available from: template service plan มะเร็ง ตัวชี้วัด 66-70 .pdf
Feng Y, Wang Y, Xie Y, Wu S, Li Y, Li M. Nomograms predicting the overall survival and cancer-specific survival of patients with stage IIIC1 cervical cancer. BMC Cancer [Internet]. 2021;21(1):450. Available from: http://dx.doi.org/10.1186/s12885-021-08209-5
Cancer survival in England. (n.d.). NHS England Digital. Retrieved October 17, 2024, from https://digital.nhs.uk/data-and-information/publications/statistical/cancer-survival-in-england
Betts P, Mokry B, Risser D, Weiss N, Williams MA, Sjoberg E, et al. Cancer Facts & Figures 2004. 2004 [cited 2024 Oct 17]; Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2024-cancer-facts-figures.html
Vali M, Maleki Z, Nikbakht H-A, Hassanipour S, Kouhi A, Nazemi S, et al. Survival rate of cervical cancer in Asian countries: a systematic review and meta-analysis. BMC Womens Health [Internet]. 2023;23(1). Available from: http://dx.doi.org/10.1186/s12905-023-02829-8
Wannasin R, Likitdee N, Kelly M, Thinkhamrop K. Survival after diagnosis of cervical cancer patients at a tertiary referral hospital in Northeast Thailand. Asian Pac J Cancer Prev [Internet]. 2023;24(5):1759–67. Available from: http://dx.doi.org/10.31557/APJCP.2023.24.5.1759
Salvo G, Odetto D, Pareja R, Frumovitz M, Ramirez PT. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. Int J Gynecol Cancer [Internet]. 2020;30(6):873–8. Available from: http://dx.doi.org/10.1136/ijgc-2020-001257
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Thailand's National Cancer Institute Foundation
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
